ADALTA LIMITED (1AD)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
1AD - ADALTA LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.008
24 Mar |
OPEN $0.01 |
HIGH $0.01 |
1,745,000 LOW $0.01 |
-0.001| OTHER COMPANIES IN THE SAME SECTOR | |||
| ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
EPS Basic
- Negative
- Growth
- Slowing
DPS All
- Negative
- Growth
- Slowing
Sales/Revenue
- Negative
- Growth
- Slowing
Book Value Per Share
- Negative
- Growth
- Slowing
Net Operating Cash Flow
- Negative
- Growth
- Slowing
Net Profit Margin
- Negative
- Growth
- Slowing
Return on Capital Employed
- Negative
- Growth
- Slowing
Return on Invested Capital
- Negative
- Growth
- Slowing
Return on Assets
- Negative
- Growth
- Slowing
Return on Equity
- Negative
- Growth
- Slowing
Return on Total Capital
- Negative
- Growth
- Slowing
Free Cash Flow ex dividends
- Negative
- Growth
- Slowing
Short-Term Debt
- Negative
- Growth
- Slowing
Long Term Debt
- Negative
- Growth
- Slowing
Total Debt
- Negative
- Growth
- Slowing
Goodwill - Gross
Cash & Equivalents - Generic
- Negative
- Growth
- Slowing
Price To Book Value
- Negative
- Growth
- Slowing
Capex
- Negative
- Growth
- Slowing
Capex % of Sales
- Negative
- Growth
- Slowing
Cost of Goods Sold
- Negative
- Growth
- Slowing
Selling, General & Admin. Exp & Other
- Negative
- Growth
- Slowing
Research & Development
- Negative
- Growth
- Slowing
Investments - Total
- Negative
- Growth
- Slowing
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
1AD STOCK CHART
FNArena News on 1AD
| 1 |
Weekly Ratings, Targets, Forecast Changes – 19-08-19Aug 19 2019 - Weekly Reports |
| 2 |
AdAlta Advances With Pulmonary Fibrosis TreatmentSep 14 2016 - Small Caps |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Behring Margin Outlook Still Main Game For CSLFeb 13 2025 - Australia |
| 2 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
| 3 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |
| 4 |
Dr Boreham’s Crucible: Aroa BiosurgeryJul 29 2024 - Small Caps |
| 5 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
| 6 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
| 7 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
| 8 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Radiopharm TheranosticsJul 03 2024 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |